Metabolic syndrome in patients with adrenocortical adenoma

Abstract

To investigate the prevalence and characteristics of metabolic syndrome (MS) in patients of adrenocortical adenoma. MS-related indexes, including waist circumference (WC), blood pressure, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose, plasma and urinary aldosterone, plasma potassium, basic and upright plasma renin activity (PRA), plasma and urinary cortisol, and plasma ACTH, were examined among 61 patients of aldosterone producing adenoma (APA, Group 1), 23 patients of cortisol-secreting adenoma (CSA, Group 2), 24 patients of nonfunctional adrenal adenoma (NAA, Group 3), and 26 healthy controls (Group 4). As defined by the National Cholesterol Education Program Adult Treatment Panel III criteria, the prevalence rates of MS were 27.9%, 39.1%, 16.7%, and 11.5% in Groups 1, 3, 3, and 4. The abdominal obesity rate was 26.2% in Group 1 and 9.1% in Group 2, both significantly higher than those of Group 3 and 4 (20.8% and 15.4% respectively). The prevalence rates of hypertension and systolic blood pressure were the highest in Group 1, followed by Group 2, 3, and 4 t. The diastolic blood pressure in patients of Group 1 was also higher than those of the other three groups. The prevalence rates of hypertriglyceride were 24.6%, 52.2%, 21.7%, and 23.1% in Group 2 1 approximately 4. The prevalence rates of low HDL-C was 32.8%, 47.8%, 30.4%, and 26.9% respectively. The prevalence rates of hyperglycemia were 13.1%, 26.1%, 8.7%, and 7.7% respectively. Patients with adrenocortical adenoma have a significantly high prevalence of metabolic syndrome, especially the patients of CSA and NAA.